il filo

In 2002, a study called the Women's Health Initiative published findings that sent hormone therapy prescriptions off a cliff. HRT, then the gold standard for treating menopausal symptoms, was linked to increased risks of breast cancer, heart attack, and stroke. The headlines were everywhere. Women stopped taking it. Doctors stopped prescribing it. A generation of women suffered unnecessarily — and largely in silence.

There was one significant problem with the study. Seventy percent of its participants were over 60 and more than a decade past menopause. They were all given the same synthetic hormone combination — Prempro — regardless of their individual health profiles. The study was designed to test whether hormone therapy could prevent chronic disease in older women, not to assess the benefits of treating menopausal symptoms in newly menopausal women. The media did not make that distinction. The panic was total.

The reappraisal has been building for years, but 2025 was the turning point. In July, the FDA convened an expert panel specifically to examine whether the black box warnings on hormone therapy were still warranted. In November, the FDA announced the removal of those warnings from all estrogen-containing HRT products used for menopausal symptoms.

What the current evidence actually supports: hormone therapy remains the most effective treatment for hot flashes, night sweats, vaginal dryness, sexual dysfunction, and mood changes. For women under 60 or within ten years of menopause onset who have low-to-average cardiovascular and breast cancer risk, the benefits are likely to outweigh the risks. The synthetic progestin used in the original WHI study carries different risks than the bioidentical progesterone now commonly prescribed — a distinction that was absent from the original panic.

What this means practically: if you have been avoiding this conversation with your doctor because of something you heard or read in 2002, this is the year to have it. The clinical guidance has shifted materially. The conversation your doctor can now have with you is different from the one that was available twenty years ago.

The femtech market was valued at $63 billion in 2025. It is projected to reach $267 billion by 2035. For a sector that spent most of its early history focused on fertility tracking apps for women in their twenties, this is a remarkable pivot — and most of the new money is flowing toward menopause.

The numbers behind the shift are straightforward: approximately 6,000 American women enter menopause every day, and only 25% of symptomatic women are currently receiving treatment despite 87% having tried some kind of remedy. That gap between need and treatment is what capital calls an opportunity. Midi Health raised $65 million in 2024 to scale its virtual menopause care platform. Maven Clinic reached a $1.7 billion valuation. Flo Health raised $200 million and announced an expansion into menopause. Sheryl Sandberg and Amy Schumer are among the celebrity investors who backed Midi.

The more interesting signal, though, is the B2B pivot. The most durable femtech businesses are no longer selling directly to women — they are selling to employers, who are discovering that untreated menopause is a productivity and retention problem that costs them more than the solutions. Maven Clinic's data shows a 2:1 clinical ROI from employer-sponsored menopause care. When employers start paying for it, the market matures fast.

What this means for her: the products and platforms available to her in 2025 are meaningfully better than what existed in 2020, and the best of them are clinically grounded, not just wellness-adjacent. The challenge is distinguishing between them — which is exactly what this issue is for.

The menopause market now contains multitudes: virtual care platforms staffed by actual clinicians, supplement brands with no clinical evidence and beautiful packaging, apps that track symptoms and deliver evidence-based guidance, apps that track symptoms and deliver inspirational quotes, hormone therapy telemedicine services with real prescription authority, and wellness companies that use the word "hormones" as a marketing device without any actual hormone involvement.

The companies worth your time share certain characteristics. They cite specific clinical evidence — not just "studies show" but named studies with sample sizes and methodologies. They are transparent about what their products can and cannot do. They involve physicians, not just wellness coaches. And they are honest about the distinction between treating symptoms and preventing disease — a line that some of the more aggressive marketing blurs deliberately.

The platforms doing the most serious work right now are the telemedicine menopause care services that connect women with physicians who actually specialize in menopause — a specialty that, remarkably, most OBGYNs do not have significant training in. The Menopause Society certifies practitioners; their provider finder is a useful starting point for anyone looking for genuinely qualified care.

The research emerging from The Menopause Society's 2025 Annual Meeting should be required reading for every woman who thinks menopause is primarily about hot flashes. It is not.

Women face a higher risk than men of developing both cardiovascular disease and Alzheimer's disease. New research presented in October 2025 found that earlier menopause significantly compounds cardiovascular risk in ways that directly accelerate cognitive decline. The mechanism is clear: reduced cardiac output limits oxygen and nutrients to the brain, damages brain tissue, and increases the risk of the silent strokes that are a precursor to dementia. Earlier menopause — defined as before age 49 — is associated with a 27% higher risk of metabolic syndrome and meaningfully elevated risk of Alzheimer's dementia later in life.

A 2024 study published in Neurology found that earlier menopause combined with higher cardiovascular risk creates a compounding effect on cognitive function — the combination being significantly worse than either factor alone. The estrogen depletion that characterizes menopause accelerates biological aging as measured through epigenetic changes and is associated with increased risk not just of dementia but of a range of age-related multi-organ conditions.

The actionable implication is this: the menopausal transition is the moment to get serious about cardiovascular health. Blood pressure, cholesterol, blood glucose, weight. These are not separate concerns from menopause — they are directly connected to how menopause will affect your brain in the decades ahead. The conversation about hormone therapy is also relevant here; the same timing hypothesis that applies to symptom relief also applies to the cardiovascular and neurological benefits — earlier is better than later.

The skin consequences of menopause are real and well-documented: declining estrogen reduces collagen production, decreases skin thickness, reduces elasticity and hydration, and slows wound healing. The question is not whether menopause affects skin — it does, measurably — but which of the products claiming to address it are actually supported by evidence.

Empelle (MEP Technology): Empelle uses a cosmeceutical ingredient called methyl estradiolpropanoate (MEP) — a "soft drug" that claims to stimulate the estrogen receptor pathway locally without increasing systemic estrogen levels or cancer risk. A 14-week placebo-controlled study published in the Journal of Drugs in Dermatology found statistically significant improvement in skin dryness, laxity, atrophy, and dullness compared to placebo, with a separate 2019 study showing a 64% decrease in wrinkles after eight weeks. These are real studies with real controls. The evidence is not definitive — the sample sizes are modest and longer-term data is limited — but it is more than most skincare brands offer.

Topical estriol creams (prescription): The evidence base here is considerably stronger. A comprehensive 2025 review in JAAD Reviews examining 14 human clinical studies found consistent improvements in skin elasticity, hydration, collagen content, and thickness from topical estrogen application. Alloy's prescription estriol cream showed 88% improvement in elasticity and 70% improvement in hydration after 12 weeks in a double-blind placebo-controlled trial. These are prescription products, not cosmetics — and that distinction matters, because it means a physician is involved in the decision.

The Mayo Clinic has estimated that menopause costs U.S. employers $1.8 billion annually in lost working time. AARP research puts global productivity losses at $150 billion, with related healthcare costs exceeding $600 billion. A Catalyst survey of nearly 2,900 women found that one in ten had declined a job opportunity because of a lack of menopause support in the workplace. These are not fringe statistics.

The mechanism is well-documented: women experiencing severe menopause symptoms are significantly more likely to report absenteeism, reduced performance, and career decisions including quitting, retiring early, or declining promotions. Fatigue, brain fog, memory disruption, and disrupted sleep are not trivial inconveniences in a demanding professional environment. They are the conditions under which women at the height of their earning power and organizational influence are quietly stepping back.

The UK has moved faster than the U.S. on this. Several major British employers now have formal menopause workplace policies, and the conversation about workplace accommodation has shifted from fringe to mainstream. In the U.S., some Fortune 500 companies have begun offering flexible arrangements and menopause-specific healthcare benefits, but they remain the exception. Stanford research has documented that women take a substantial and lasting earnings hit during the menopausal transition — financial consequences that compound over time through lower Social Security benefits, reduced retirement savings, and interrupted career trajectories.

What to do with this: if you are experiencing symptoms that are affecting your work, you are not alone, you are not making it up, and the medical options available to you in 2025 are considerably better than they were five years ago. The conversation with your doctor is the first step. The conversation with HR about what support exists is the second. Both are worth having.

Here is the thing about the menopause reckoning that gets lost in the market coverage, the investment stories, and the skincare debates: for twenty-three years, a flawed study scared women away from a treatment that would have helped them. Millions of women suffered hot flashes, insomnia, cognitive fog, joint pain, and sexual dysfunction — sometimes for years — because their doctors were afraid to prescribe, because the warnings were too scary, because a study that was not designed to answer their question had been interpreted as if it were.

The women who navigated those years without adequate information were not weak or uninformed. They were failed by a system that, as usual, had not been designed with them at its center. The study that shaped twenty years of clinical practice used a population that did not represent the women most in need of treatment. The media coverage stripped out the nuance. The warnings remained on the labels long after the evidence had shifted.

The opportunity: there are now more evidence-based options, more specialized physicians, and more clinical-grade tools available to menopausal women than at any point in the past two decades. The warning: not everything that claims to address menopause is worth your money, your time, or your trust. The sorting work matters.

What she actually needs to know is not complicated. Find a physician who specializes in menopause — the Menopause Society's provider finder is the place to start. Have the hormone therapy conversation without the fear that was manufactured by a misread study. Treat your cardiovascular health as the neurological investment it is. Be skeptical of any skincare product that does not cite specific clinical evidence for its specific ingredient. Advocate in your workplace if symptoms are affecting your performance, because the data supporting your position is now unambiguous.

And know that the reckoning — the science being corrected, the capital arriving, the conversation moving from whisper to mainstream — is not happening because the market discovered you. It is happening because you were always here, and the demand was always real, and eventually reality wins.